Success Stories: A Chemist from India Not Only Secured NIW Approval but Also Got Employer-Petitioned EB-1B Approved Miraculously in Just 3 Days
Client’s Testimonial:
“I would like to convey my gratitude to you for guiding me through this critical process. I would certainly recommend your law firm to those who are in need. I appreciate your professionalism, agility, and timely activities that enabled the entire process to go through smoothly. Thank you so much again.”
On January 14th, 2021 and June 10th, 2021, we received another EB-2 NIW (National Interest Waiver) and EB-1B (Outstanding Professors and Researchers) approval for a Chemist in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Chemist
Country of Origin: India
State of Residence at the Time of Filing: Virginia
Approval Notice Date: January 14th, 2021 (NIW) and June 10th, 2021 (EB-1B)
Processing Time: 12 months (NIW) and 3 days (EB-1B) (Premium Processing Requested)
Case Summary:
A chemist from India approached North America Immigration Law Group to help him file an EB-2 NIW (National Interest Waiver) petition. When we agreed to take his case ahead, within 5 months he decided to retain our law firm to file another petition under the I-140 EB-1B (Outstanding Professors and Researchers) visa category. Before we led him to the EB1B success, our proficient team ensured that our client’s employer was compliant with providing us with the required documents for building our client’s EB1B petition. After we completed a thorough assessment of his credibility and extraordinary accomplishments in his proposed field of medicinal chemistry, we aimed to prove to the USCIS how our client’s vital experience in the medicinal chemistry field has allowed his research to be innovative, with applications such as drug development and the treatment of diseases such as the hepatitis C virus and cancer. Therefore, we prepared his respective petition packets with the below-mentioned information:
- We highlighted his record of authorship (13 peer-reviewed scientific articles (8 first-authored), 1 patent, and 1 patent application), consistently got published in top-ranked journals, demonstrating that his work has been recognized as some of the best in the field. Also, he has conducted 30 peer reviews for highly acclaimed journals in his field. Thus, this remarkable description of his peer review activity emphasizes the groundbreaking disposition of his research.
- Also, we noted the citation metrics signifying that his work has seen widespread implementation in subsequent medicinal chemistry studies, accumulating 177 citations from several scholars from notable institutions across the globe.
- We evaluated his research on compounds for targeting biologically important enzymes in medicinal chemistry, addressing some of the most pressing issues of our country, mainly in understanding compounds for targeting biologically important enzymes. Moreover, his research has repeatedly exemplified its stature throughout the field, being funded by the National Science Foundation (NSF) and National Institutes of Health (NIH), additionally attesting to the recognized importance of his work throughout the field. In addition, he has been vital to the development of drugs for the treatment of ADHD, which has recently been approved by the U.S. Food and Drug Administration (FDA). Considering this recounted recognition of the importance of his work, his studies must continue to be supported.
- We also supplemented his petition packets with five recommendation letters. Two of his recommenders stated the following:
“This combination of practical clinical use and scholarly distinction makes [client] unique in his field. His research accelerates the pace of research on novel therapeutics for diseases such as hepatitis C, while also identifying new and actionable avenues for drug discovery. Thus, he is combating public health crises in America with unparalleled aptitude.” & “It is therefore critically important that [client] is allowed to continue his work uninterrupted in the United States. As a chemist, a leading developer in the pharmaceutical industry, he is producing important research that is of extraordinary influence both within his field and throughout the medical sciences at large.”
Yet again, we persuaded USCIS of how our client’s work must be allowed to continue here in the U.S. for the sake of the academic field and public health. Given his ubiquitous record of success, we are certain that he is certainly one of the most adept authorities in his specialized area of study. Therefore, USCIS granted him the NIW as well as EB1B petition approvals. In comparison to his NIW case adjudication duration, his EB1B got approved in just 3 days, thanks to a premium processing upgrade. We congratulate him on achieving this milestone. Also, we wish him the best as he advances his future projects here in the United States.**Premium Processing Upgrade: It is a paid option offered by the USCIS that allows petitioners to enjoy accelerated adjudication (the case will be processed within 15 days instead of 9-12 months).**